Company news
Rezolute, Inc. news in 2021
Rezolute, Inc.'s news releases, calls and decks from 2021, newest first.
Rezolute Reports First Quarter Fiscal 2022 Financial Results and Highlights Recent Company Progress
November 11, 2021
Rezolute Announces Pricing of Public Offering of $55 million of Common Stock and Pre-Funded Warrants, and Concurrent Registered Direct Offering
October 12, 2021
Rezolute Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants, and a Concurrent Registered Direct Offering
October 11, 2021
Rezolute Presents Results from Two-Week Natural History Study in Congenital Hyperinsulinism Patients on Standard of Care Therapies at ESPE 2021
September 21, 2021
Rezolute Reports Fourth Quarter and Full Year Fiscal 2021 Financial Results and Highlights Recent Company Progress
September 14, 2021
Rezolute Announces Initiation of Dosing in the Second Cohort of its Phase 2b Trial of RZ358 for Congenital Hyperinsulinism
September 8, 2021
Rezolute to Participate in Upcoming Virtual Healthcare Conferences
September 6, 2021
Rezolute Announces Initiation of Multiple-Ascending Dose Study of RZ402, Rezolute’s Oral PKI for Treatment of DME
August 9, 2021
Rezolute Added to Russell Microcap® Index
June 27, 2021
Rezolute Expands Leadership Team with the Appointment of Davelyn Hood, MD as Director, Scientific and Patient Affairs
May 19, 2021
Rezolute Appoints Leading Ophthalmology Expert, Quan Dong Nguyen, MD, MSc, FAAO, FARVO, to Scientific Advisory Board
May 17, 2021
Rezolute to Present at the Oppenheimer Rare and Orphan Disease Summit
May 16, 2021
Rezolute Reports Third Quarter Fiscal 2021 Financial Results and Highlights Recent Company Progress
May 16, 2021
Rezolute Announces Positive RZ402 Study Results Demonstrating Potential for Once Daily Dosing of an Oral Plasma Kallikrein Inhibitor for Diabetic Macular Edema
May 3, 2021
Rezolute Announces $30 Million Debt Financing Agreement with SLR Capital Partners
April 18, 2021
Rezolute Presents Data on RZ358 in Post-Gastric Bypass Hypoglycemia at ENDO 2021
March 21, 2021
Rezolute Strengthens Board of Directors with Key Appointments of Leading Rare Disease Experts
March 7, 2021
Rezolute to Participate in Upcoming Investor Conferences in March
March 1, 2021
Rezolute Reports Second Quarter Fiscal 2021 Financial Results
February 9, 2021
Rezolute Announces Initiation of Phase 1 Study of RZ402, an Oral Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema
January 11, 2021